Latest & greatest articles for migraine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on migraine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on migraine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for migraine

1. Acupuncture for migraine headaches

Acupuncture for migraine headaches Acupuncture for migraine headaches Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Acupuncture for migraine headaches View/ Open Date 2010-04 Format Metadata Abstract Acupuncture reduces the frequency of migraine headaches when used as an adjunct to, or in place of, medical management

Clinical Inquiries2018

2. “Triptans” can relieve migraines in children and adolescents

“Triptans” can relieve migraines in children and adolescents Signal - “Triptans” can relieve migraines in children and adolescents Dissemination Centre Discover Portal NIHR DC Discover “Triptans” can relieve migraines in children and adolescents Published on 13 September 2016 Triptans, a migraine medication, relieve migraine headache completely within two hours compared to placebo. Ibuprofen was also effective but less well studied. This review was also reassuring in that any side effects (...) of treatment were mild. Most evidence identified in this Cochrane review was for sumatriptan, a commonly prescribed treatment for adults, compared to placebo or dummy pills. A few studies examined other triptans or other painkillers, such as ibuprofen or paracetamol against placebo in children and adults. The findings support current guideline recommendations to prescribe nasal triptans for migraine in adolescents. Only nasal preparations are currently licensed for adolescents, whereas oral administration

NIHR Dissemination Centre2018

3. Acupuncture shows promise for preventing episodic migraines

Acupuncture shows promise for preventing episodic migraines Signal - Acupuncture shows promise for preventing episodic migraines Dissemination Centre Discover Portal NIHR DC Discover Acupuncture shows promise for preventing episodic migraines Published on 18 October 2016 Acupuncture was about as effective as long term medication in reducing the number of migraines. There were fewer adverse events amongst people receiving acupuncture (16-17%) compared to drug treatment (34%). Migraines affect (...) , in reality, only be available to people living in certain areas or who can afford to pay for treatment themselves. Share your views on the research. Why was this study needed? Migraines are common, affecting around one in five women and one in 15 men. Symptoms include headache, visual disturbances and nausea, which can be severe enough to stop people living their normal daily life. Migraine attacks last anywhere between four and 72 hours and are estimated to cost the UK economy as much as £2 billion

NIHR Dissemination Centre2018

4. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study 30446596 2018 12 11 1526-632X 91 24 2018 Dec 11 Neurology Neurology Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. e2211-e2221 10.1212/WNL.0000000000006640 To evaluate the efficacy and safety of galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, in the preventive treatment of chronic migraine (...) . A phase 3, randomized, double-blind, placebo-controlled study of LY2951742 in patients with chronic migraine (Evaluation of Galcanezumab in the Prevention of Chronic Migraine [REGAIN]) was a phase 3 study with a 3-month double-blind, placebo-controlled treatment phase and a 9-month open-label extension. Eligible patients 18 to 65 years of age with chronic migraine were randomized 2:1:1 to monthly subcutaneous injections of placebo (n = 558), galcanezumab 120 mg (with a 240-mg loading dose, n = 278

EvidenceUpdates2018

5. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study 30446595 2018 12 11 1526-632X 91 24 2018 Dec 11 Neurology Neurology Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. e2222-e2232 10.1212/WNL.0000000000006641 To assess the efficacy and safety of lasmiditan in the acute treatment of migraine. Adult patients with migraine were randomized (1:1:1) to a double-blind dose of oral lasmiditan 200 mg, lasmiditan 100 mg, or placebo (...) and were asked to treat their next migraine attack within 4 hours of onset. Over 48 hours after dosing, patients used an electronic diary to record headache pain and the presence of nausea, phonophobia, and photophobia, one of which was designated their most bothersome symptom (MBS). Of the 1,856 patients who treated an attack, 77.9% had ≥1 cardiovascular risk factors in addition to migraine. Compared with placebo, more patients dosed with lasmiditan 200 mg were free of headache pain at 2 hours after

EvidenceUpdates2018

6. Galcanezumab gnlm (Emgality) - For the preventive treatment of migraine in adults

Galcanezumab gnlm (Emgality) - For the preventive treatment of migraine in adults Drug Approval Package: Emgality (galcanezumab-gnlm) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Emgality (galcanezumab-gnlm) Company: Eli Lilly and Company Application Number: 761063 Approval Date: 09/27/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF

FDA - Drug Approval Package2018

7. Fremanezumab vfrm (Ajovy) - For the preventive treatment of migraine in adults

Fremanezumab vfrm (Ajovy) - For the preventive treatment of migraine in adults Drug Approval Package: Ajovy (fremanezumab-vfrm) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Ajovy (fremanezumab-vfrm) Company: Teva Pharmaceuticals USA, Inc. Application Number: 761089 Approval Date: 09/14/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF

FDA - Drug Approval Package2018

8. Migraine headache in adults

Migraine headache in adults Migraine headache in adults - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Migraine headache in adults Last reviewed: September 2018 Last updated: August 2018 Important updates Erenumab approved in the EU for the prevention of migraine Erenumab, a novel treatment for migraine prevention, has been approved by the European Medicines Agency (EMA) for the prophylaxis of migraine in adults who (...) have at least 4 migraine days per month. Erenumab is a first-in-class fully human monoclonal antibody that works by inhibiting the calcitonin gene‑related peptide (CGRP) receptors. The CGRP is believed to play a causal role in the pathophysiology of migraine. Erenumab is administered as a once-monthly subcutaneous injection. According to the EMA, the benefit of erenumab treatment is its ability to reduce the number of monthly migraine days. In two trials involving 667 patients with chronic migraine

BMJ Best Practice2018

9. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. BACKGROUND: A substantial proportion of patients with migraine does not respond to, or cannot tolerate, oral preventive treatments. Erenumab is a novel CGRP-receptor antibody with preventive efficacy in migraine. We assessed its efficacy and tolerability in patients with episodic migraine (...) in whom previous treatment with two-to-four migraine preventives had been unsuccessful. METHODS: LIBERTY was a 12-week, double-blind, placebo-controlled randomised study at 59 sites in 16 countries. Eligible patients were aged 18-65 years and had a history of episodic migraine with or without aura for at least 12 months, had migraine for an average of 4-14 days per month during the 3 months before screening, and had been treated unsuccessfully (in terms of either efficacy or tolerability, or both

Lancet2018

10. The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis

The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2018\/10\/cover.png"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Oct 19 2018 (...) The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis By in , , Journal reference: Gaul C, Diener HC, Danesch U, Migravent Study G. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 2015;16:516. Link: Published: April 2015 Evidence cookie says… The evidence for combination magnesium, riboflavin, and CoQ10 is at best equivocal for migraine

Morsels of Evidence2018

11. Fremanezumab for preventive treatment of migraine: Functional status on headache-free days

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days 30120138 2018 08 18 1526-632X 2018 Aug 17 Neurology Neurology Fremanezumab for preventive treatment of migraine: Functional status on headache-free days. 10.1212/01.wnl.0000544321.19316.40 10.1212/01.wnl.0000544321.19316.40 To evaluate the effect of fremanezumab on the functional status on headache-free days in phase 2 episodic migraine (EM) and chronic migraine (CM) studies. Functional status data were (...) with fremanezumab. There was an increased number of headache-free days with normal functional performance on all measures for the patients with EM and some measures for patients with CM in the fremanezumab-treated groups. Further research is required to confirm these findings in a prospective study and to clarify the underlying mechanism(s). NCT02025556 and NCT02021773. This study provides Class II evidence that for patients with migraine, fremanezumab increases normal functional performance on headache-free

EvidenceUpdates2018

12. Common migraine prevention treatments found to be equally effective

Common migraine prevention treatments found to be equally effective Signal - Common migraine prevention treatments found to be equally effective Dissemination Centre Discover Portal NIHR DC Discover Common migraine prevention treatments found to be equally effective Published on 24 September 2015 This review found that the main drugs used for preventing migraine were all effective compared with placebo or dummy treatment. The results were less clear cut when comparing drugs directly against (...) each other as there were fewer trials. This review highlights the range of drugs used to prevent migraines, reflecting the number of possible treatments available. The review’s conclusions suggest that the prescriber could be guided by individual patient characteristics, including preferences, pre-existing conditions and potential side effects. This review confirms and strengthens NICE guidance in this area. Share your views on the research. Why was this study needed? Migraines affect around 15

NIHR Dissemination Centre2018

13. Erenumab (Aimovig) - Migraine

Erenumab (Aimovig) - Migraine 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 31 May 2018 EMA/CHMP/413393/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Aimovig International non-proprietary name: erenumab Procedure No. EMEA/H/C/004447/0000 Note Assessment report as adopted by the CHMP with all (...) Amgen Thousand Oaks BMI body mass index CDC complement dependent cytotoxicity CEX cation exchange CFU colony-forming unit cGMP current good manufacturing practices CGRP calcitonin gene-related peptide CHO chinese hamster ovary CI confidence interval CM chronic migraine CMH Cochran-Mantel-Haenszel CPP critical process parameter CPV continued process verification CQA critical quality attribute CSR clinical study report dFBS dialyzed fetal bovine serum DNA deoxyribonucleic acid DOE design

European Medicines Agency - EPARs2018

14. Migraine and Tension Headache

Migraine and Tension Headache ? 2018 Kaiser Foundation Health Plan of Washington. All rights reserved. 1 Migraine and Tension Headache Guideline Background 2 Diagnosis Red flag warning signs 2 Differential diagnosis 2 Imaging 3 Migraine versus tension headache 3 Medication overuse headache 3 Menstruation-related migraine 3 Tension Headache Acute treatment 4 Prophylaxis 5 Migraine Headache Acute treatment 6 Treatment of refractory migraine 7 Prophylaxis 8 Menstruation-related migraine (...) Background This guideline includes diagnosis and treatment of the most common headache types that are managed in primary care: • Tension headache • Migraine headache, including menstrual migraine • Medication overuse headache (also known as rebound headache) Cluster headaches are excluded from this guideline because of their low prevalence in the general population and the severity of the symptoms. For patients with suspected cluster headaches, consider consulting with Neurology for evaluation

Kaiser Permanente Clinical Guidelines2018

15. Migraine

Migraine Top results for migraine - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for migraine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

16. Migraine

Migraine Autosynthesis - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search

Trip Evidence Maps2018

17. Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study

Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study 29907608 2018 06 16 1526-632X 2018 Jun 15 Neurology Neurology Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. 10.1212/WNL.0000000000005857 10.1212/WNL.0000000000005857 To evaluate the efficacy, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS; gammaCore; electroCore, LLC, Basking Ridge, NJ) for the acute treatment of migraine (...) in a multicenter, double-blind, randomized, sham-controlled trial. A total of 248 participants with episodic migraine with/without aura were randomized to receive nVNS or sham within 20 minutes from pain onset. Participants were to repeat treatment if pain had not improved in 15 minutes. nVNS (n = 120) was superior to sham (n = 123) for pain freedom at 30 minutes (12.7% vs 4.2%; p = 0.012) and 60 minutes (21.0% vs 10.0%; p = 0.023) but not at 120 minutes (30.4% vs 19.7%; p = 0.067; primary endpoint; logistic

EvidenceUpdates2018

18. Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value

Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value ©Institute for Clinical and Economic Review, 2018 Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value Final Evidence Report July 3, 2018 Prepared for ©Institute for Clinical and Economic Review, 2018 Page ii Final Evidence Report – CGRP Inhibitors (...) for Episodic or Chronic Migraine ICER Staff and Consultants University of Illinois, Chicago Modeling Group Alexandra G. Ellis, PhD Senior Scientist, HTA and Economic Evaluation Institute for Clinical and Economic Review Ifeoma Otuonye, MPH Research Lead, Evidence Synthesis Institute for Clinical and Economic Review Varun Kumar, MBBS, MPH, MSc Health Economist Institute for Clinical and Economic Review Rick Chapman, PhD, MS Director of Health Economics Institute for Clinical and Economic Review Matt Seidner

California Technology Assessment Forum2018

19. Botulinum toxins for the prevention of migraine in adults.

Botulinum toxins for the prevention of migraine in adults. BACKGROUND: Migraine occurs in around 15% of adults and is ranked as the seventh most disabling disease amongst all diseases globally. Despite the available treatments many people suffer prolonged and frequent attacks which have a major impact on their quality of life. Chronic migraine is defined as 15 or more days of headache per month, at least eight of those days being migraine. People with episodic migraine have fewer than 15 (...) headache days per month. Botulinum toxin type A has been licensed in some countries for chronic migraine treatment, due to the results of just two trials. OBJECTIVES: To assess the effects of botulinum toxins versus placebo or active treatment for the prevention or reduction in frequency of chronic or episodic migraine in adults. SEARCH METHODS: We searched CENTRAL, MEDLINE & MEDLINE in Process, Embase, ClinicalTrials.gov and World Health Organization International Clinical Trials Registry

Cochrane2018

20. Erenumab-aooe (Aimovig) - For the preventive treatment for migraine

Erenumab-aooe (Aimovig) - For the preventive treatment for migraine Drug Approval Package: Aimovig (erenumab-aooe) injection U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Aimovig (erenumab-aooe) injection Company: Amgen, Inc. Application Number: 761077 Approval Date: 05/17/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application

FDA - Drug Approval Package2018